Hair-sparing Whole Brain Radiotherapy
Up to 10% of patients with cancer will develop symptomatic brain metastases. Given this limited survival it is important to consider quality of life (QOL) when treating these patients. Whole brain radiotherapy (WBRT) can increase survival to 6 month. However, WBRT itself has been shown to reduce QOL by increasing drowsiness, leg weakness and hair loss in patients with brain metastases. Both fatigue and hair loss were reported to have the largest decline in QOL scores when WBRT is used in the prophylactic setting in small cell lung cancer. Recent technological improvements in patient positioning and treatment planning will allow us to treat the whole brain with reduced margins, allowing better sparing of the scalp. In view of the large impact of hair loss on quality of life, the investigators hypothesize to see an improved quality of life with scalp sparing techniques.
Study hypothesis: Volumetric arc therapy results in a reduced hair loss and a subsequent clinically important improvement in QOL.
|Brain Metastases Small Cell Lung Cancer||Radiation: Whole brain radiotherapy with volumetric arc therapy||Phase 2|
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Reducing Hair Loss With Volumetric Arc Therapy in Patients Treated With Whole Brain Radiotherapy: a Phase II Trial|
- The European Organization for Research and Treatment of Cancer (EORTC)quality of life questionnaire (C15-PAL and BN20) measured at 1 month following treatment. [ Time Frame: At 1 month. ]Quality of life questionnaires are used.
- Hair quality before treatment and at 1 month following treatment. [ Time Frame: at 1 month following treatment ]Key measurements: trichogram are used.
|Study Start Date:||January 2013|
|Study Completion Date:||October 2014|
|Primary Completion Date:||September 2013 (Final data collection date for primary outcome measure)|
Radiation: Whole brain radiotherapy with volumetric arc therapy
Please refer to this study by its ClinicalTrials.gov identifier: NCT01421316
|Ghent University Hospital, Belgium|